https://comparerx.org/news/roche-2-5-billion-obesity-deal-akeso CompareRx.org en 2026-08-29T00:15:33.812Z Roche expands obesity pipeline with $2.5B Akeso deal — challenging Lilly and Novo's market grip https://comparerx.org/news/wegovy-study-reveals-high-one-year-dropout-rates CompareRx.org en 2026-08-28T20:15:29.349Z Half of Wegovy patients quit within a year — what high dropout rates mean for cash-paying US buyers https://comparerx.org/news/fda-approves-mounjaro-cardiovascular-risk-reduction CompareRx.org en 2026-08-28T16:15:31.426Z FDA approves Mounjaro for cardiovascular risk reduction — matching a key Novo Nordisk advantage https://comparerx.org/news/dolly-parton-dies-employers-cut-glp1-coverage CompareRx.org en 2026-08-28T00:15:28.712Z Dolly Parton dies at 80 — as 14% of employers plan to cut GLP-1 coverage https://comparerx.org/news/medicare-50-glp1-pilot-excludes-comorbidities-telehealth CompareRx.org en 2026-08-27T20:15:31.639Z Medicare excludes sickest seniors from $50 GLP-1 pilot — driving buyers to telehealth cash options